<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02973659</url>
  </required_header>
  <id_info>
    <org_study_id>0471-14-TLV</org_study_id>
    <nct_id>NCT02973659</nct_id>
  </id_info>
  <brief_title>The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar.</brief_title>
  <official_title>The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary focal hyperhidrosis interferes with daily activities. Limited efficacy, costs, side&#xD;
      effects and complications are issues of concern for most current therapeutic modalities. In&#xD;
      this study the invetigators aim to evaluate the efficacy of topical oxybutynin 10% gel in&#xD;
      treating primary focal hyperhidrosis. 60 patients with primary focal hyperhidrosis will be&#xD;
      recruited. Topical oxybutynin 10% gel will be assigned to the right or left axilla, palm or&#xD;
      sole and a placebo compound to the contralateral side for a total of 30 days. The&#xD;
      Hyperhidrosis Disease Severity Scale (HDSS) and Dermatology Life Quality Index (DLQI)&#xD;
      questionnaires will be administered before and after treatment, and 2 noninvolved blinded&#xD;
      physicians will score the results using starch-iodine tests. The participants will grade the&#xD;
      sweat reduction on both sides and rated their satisfaction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be performed at the Tel Aviv Medical Center. Written informed consent will be&#xD;
      obtained from all 60 participants prior to entering the study. patients with primary focal&#xD;
      hyperhidrosis (palmar hyperhidrosis, axillary hyperhidrosis, plantar hyperhidrosis) who&#xD;
      receive no topical or oral anticholinergics, iontophoresis treatment or botulinum toxin&#xD;
      injections during the 6 months prior to study entry and did not undergone sympathectomy will&#xD;
      be recruited. Demographic data, including gender, age and medical history will be collected&#xD;
      before enrollment in the study, and the following patients will be excluded: pregnant or&#xD;
      lactating women, individuals with conditions that may cause secondary hyperhidrosis,&#xD;
      individuals with a history of eczema, seborrhea, psoriasis, glaucoma, micturition disorder,&#xD;
      gastric retention, myasthenia gravis, angioedema, Sjögren's syndrome, or Sicca syndrome, and&#xD;
      candidates older than 60 years or younger than 18 years.&#xD;
&#xD;
      The study will follow a prospective, randomized, double blind, placebo-controlled design.&#xD;
      Each participant will be given a pair of test jars (designated as &quot;'gel A&quot;' and &quot;'gel B&quot;').&#xD;
      The investigators will use a designated software to randomize the jars (either A or B) which&#xD;
      contained 10% oxybutynin gel or a placebo aqueous gel. The two jars are identical in shape,&#xD;
      size and weight, as well as color, odor and consistency. The patients will be instructed to&#xD;
      apply 1 cm of gel A or B on clean, dry and intact skin of one sweating area (right or left&#xD;
      palms, soles or axillae) twice daily for 30 days. In addition, the participants will be&#xD;
      instructed to avoid contact of the gel with the eyes, nose, mouth, and not to wash the areas&#xD;
      for 4 hours post-application. The participants will be also instructed not to use any&#xD;
      concomitant topical or systemic medication during the entire treatment period. Each jar will&#xD;
      be weighed by a digital scale before treatment initiation and on the 30th day of treatment.&#xD;
&#xD;
      The participants will interviewed twice, first at the time of screening before the initial&#xD;
      application and then following the completion of the 30th day of treatment. The participants&#xD;
      will be asked to rate the severity of their condition using the hyperhidrosis disease&#xD;
      severity scale in which a score of 3 or 4 indicates severe hyperhidrosis while a score of 1&#xD;
      or 2 indicates mild or moderate hyperhidrosis. The therapeutic results will be considered as&#xD;
      &quot;excellent&quot; or &quot;good&quot; if the patient indicate a reduction of 2 or 1 points, respectively, on&#xD;
      the HDSS score.&#xD;
&#xD;
      In addition, quality of life will be assessed by a modified Dermatology Life Quality Index.&#xD;
      The maximum score is 30, with 0 indicating a negligible effect of the disorder on the&#xD;
      patient's quality of life and 30 indicating a significant impact. A change of 0-1 point on&#xD;
      the mDLQI score will be interpreted as reflecting no effect on the patient's life, a change&#xD;
      of 2-5 points as a small effect, 6-10 points as a moderate effect, 11-20 points as a very&#xD;
      significant modification, and 21-30 points as the most significant impact possible.&#xD;
&#xD;
      At the end of the treatment, patients will complete a questionnaire evaluating the following:&#xD;
&#xD;
        1. Sweat reduction in the treated and in the control sweating areas (0 = no change, 1 =&#xD;
           poor (limited improvement with the patient being very much aware of sweating), 2 = fair&#xD;
           (marked improvement, with noticeable sweating under stressful conditions only, 3 = good&#xD;
           (marked improvement with minimal sweating under stressful conditions), and 4 = excellent&#xD;
           improvement, with cessation of sweating)&#xD;
&#xD;
        2. Global patient satisfaction (0 = dissatisfied, 1 = partially satisfied, 2 = satisfied,&#xD;
           and 3 = highly satisfied).&#xD;
&#xD;
        3. Side effects: dry mouth, headache, dizziness, urine retention, constipation and&#xD;
           application site reactions (pruritus or dermatitis).&#xD;
&#xD;
      All patients will undergo the Minor iodine-starch test. The tested area will be photographed&#xD;
      under standard conditions using the Galaxy Camera (3G) EK-GC100 photography system.&#xD;
      Photographs taken before and after 30 days of treatment will be independently assessed by two&#xD;
      dermatologists who are unaware of the study design. All pairs of photographs will be graded&#xD;
      as 0 = no change, 1 = minor change of &lt;25%, 2 = moderate change between 25-50%, 3 = major&#xD;
      change between 50-75%, and 4 = absence or near absence of sweating.&#xD;
&#xD;
      Both the study and control gels will be compounded in an Israeli compounding pharmacy.&#xD;
&#xD;
      Continuous variables will be fed into a tabular format as means ± standard errors and&#xD;
      compared using the Wilcoxon paired test. Categorical variables will be tested using the&#xD;
      Fisher exact test. Correlation between raters will evaluated using Spearman's correlation.&#xD;
      All analyses were carried out using SPSS 23.0.2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>baseline and following 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the chanhe of Hyperhidrosis Disease Severity Scale (HDSS)</measure>
    <time_frame>baseline and following 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>sweat reduction grading</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>satisfaction rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Hyperhidrosis</condition>
  <arm_group>
    <arm_group_label>patients with palmar hyperhidrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oxybutynin Vs placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with plantar hyperhidrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oxybutynin Vs placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with axillary hyperhidrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oxybutynin Vs placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxybutynin</intervention_name>
    <description>10% oxybutynin gel (one side) Vs placebo aqueous gel (other side) - 2/d application, 1 month</description>
    <arm_group_label>patients with axillary hyperhidrosis</arm_group_label>
    <arm_group_label>patients with palmar hyperhidrosis</arm_group_label>
    <arm_group_label>patients with plantar hyperhidrosis</arm_group_label>
    <other_name>anti cholinergic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <arm_group_label>patients with axillary hyperhidrosis</arm_group_label>
    <arm_group_label>patients with palmar hyperhidrosis</arm_group_label>
    <arm_group_label>patients with plantar hyperhidrosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy individuals&#xD;
&#xD;
          -  primary hyperhidrosis (axillary, palmar, plantar) diagnosed according to the&#xD;
             recommended criteria4 : focal, visible and excessive sweating of at least 6 months&#xD;
             duration without apparent cause, with at least two of the following characteristics:&#xD;
             bilateral and symmetric, impairing daily activity, more than one episode per week,&#xD;
             onset before age of 25 years, positive family history, cessation during sleep.&#xD;
&#xD;
          -  given written informed patient consent of participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known history of conditions that may cause secondary hyperhidrosis&#xD;
&#xD;
          -  eczema, seborrhea, psoriasis&#xD;
&#xD;
          -  any other active lesion on treatment site&#xD;
&#xD;
          -  any treatment for hyperhidrosis within 4 weeks&#xD;
&#xD;
          -  Any medical condition that can be aggravated by anticholinergic medications: glaucoma,&#xD;
             micturition disorders, gastric retention, myasthenia gravis, angioedema , known&#xD;
             history of Sjögren's syndrome or Sicca syndrome&#xD;
&#xD;
          -  iodine allergy&#xD;
&#xD;
          -  lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ofir Artzi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology department Tel Aviv medical center</affiliation>
  </overall_official>
  <results_reference>
    <citation>Schollhammer M, Brenaut E, Menard-Andivot N, Pillette-Delarue M, Zagnoli A, Chassain-Le Lay M, Sassolas B, Jouan N, Le Ru Y, Abasq-Thomas C, Greco M, Penven K, Roguedas-Contios AM, Dupre-Goetghebeur D, Gouedard C, Misery L, Le Gal G. Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. Br J Dermatol. 2015 Nov;173(5):1163-8. doi: 10.1111/bjd.13973. Epub 2015 Oct 14.</citation>
    <PMID>26114588</PMID>
  </results_reference>
  <results_reference>
    <citation>Wolosker N, de Campos JR, Kauffman P, Puech-Leao P. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. J Vasc Surg. 2012 Jun;55(6):1696-700. doi: 10.1016/j.jvs.2011.12.039. Epub 2012 Feb 16.</citation>
    <PMID>22341836</PMID>
  </results_reference>
  <results_reference>
    <citation>Try C, Messikh R, Elkhyat A, Aubin F, Humbert RP. [Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis]. Rev Med Liege. 2012 Oct;67(10):520-6. French.</citation>
    <PMID>23167161</PMID>
  </results_reference>
  <results_reference>
    <citation>Cartwright R, Srikrishna S, Cardozo L, Robinson D. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence. BJU Int. 2011 Jan;107(1):70-6. doi: 10.1111/j.1464-410X.2010.09508.x.</citation>
    <PMID>20626389</PMID>
  </results_reference>
  <results_reference>
    <citation>Sand PK, Davila GW, Lucente VR, Thomas H, Caramelli KE, Hoel G. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome. Am J Obstet Gynecol. 2012 Feb;206(2):168.e1-6. doi: 10.1016/j.ajog.2011.08.005. Epub 2011 Aug 11.</citation>
    <PMID>21963104</PMID>
  </results_reference>
  <results_reference>
    <citation>Staskin DR, Dmochowski RR, Sand PK, Macdiarmid SA, Caramelli KE, Thomas H, Hoel G. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol. 2009 Apr;181(4):1764-72. doi: 10.1016/j.juro.2008.11.125. Epub 2009 Feb 23.</citation>
    <PMID>19233423</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>November 6, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2016</study_first_posted>
  <last_update_submitted>November 23, 2016</last_update_submitted>
  <last_update_submitted_qc>November 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tel-Aviv Sourasky Medical Center</investigator_affiliation>
    <investigator_full_name>michal roll</investigator_full_name>
    <investigator_title>DERMATOLOGIST, HEAD, CENTER OF AESTHETIC DERMATOLOGY</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperhidrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxybutynin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02973659
org study id: 0471-14-TLV
nct id: NCT02973659
lead sponsor: 
has dmc: No
Primary focal hyperhidrosis interferes with daily activities. Limited efficacy, costs, side
      effects and complications are issues of concern for most current therapeutic modalities. In
      this study the invetigators aim to evaluate the efficacy of topical oxybutynin 10% gel in
      treating primary focal hyperhidrosis. 60 patients with primary focal hyperhidrosis will be
      recruited. Topical oxybutynin 10% gel will be assigned to the right or left axilla, palm or
      sole and a placebo compound to the contralateral side for a total of 30 days. The
      Hyperhidrosis Disease Severity Scale (HDSS) and Dermatology Life Quality Index (DLQI)
      questionnaires will be administered before and after treatment, and 2 noninvolved blinded
      physicians will score the results using starch-iodine tests. The participants will grade the
      sweat reduction on both sides and rated their satisfaction.
This study will be performed at the Tel Aviv Medical Center. Written informed consent will be
      obtained from all 60 participants prior to entering the study. patients with primary focal
      hyperhidrosis (palmar hyperhidrosis, axillary hyperhidrosis, plantar hyperhidrosis) who
      receive no topical or oral anticholinergics, iontophoresis treatment or botulinum toxin
      injections during the 6 months prior to study entry and did not undergone sympathectomy will
      be recruited. Demographic data, including gender, age and medical history will be collected
      before enrollment in the study, and the following patients will be excluded: pregnant or
      lactating women, individuals with conditions that may cause secondary hyperhidrosis,
      individuals with a history of eczema, seborrhea, psoriasis, glaucoma, micturition disorder,
      gastric retention, myasthenia gravis, angioedema, Sjögren's syndrome, or Sicca syndrome, and
      candidates older than 60 years or younger than 18 years.

      The study will follow a prospective, randomized, double blind, placebo-controlled design.
      Each participant will be given a pair of test jars (designated as "'gel A"' and "'gel B"').
      The investigators will use a designated software to randomize the jars (either A or B) which
      contained 10% oxybutynin gel or a placebo aqueous gel. The two jars are identical in shape,
      size and weight, as well as color, odor and consistency. The patients will be instructed to
      apply 1 cm of gel A or B on clean, dry and intact skin of one sweating area (right or left
      palms, soles or axillae) twice daily for 30 days. In addition, the participants will be
      instructed to avoid contact of the gel with the eyes, nose, mouth, and not to wash the areas
      for 4 hours post-application. The participants will be also instructed not to use any
      concomitant topical or systemic medication during the entire treatment period. Each jar will
      be weighed by a digital scale before treatment initiation and on the 30th day of treatment.

      The participants will interviewed twice, first at the time of screening before the initial
      application and then following the completion of the 30th day of treatment. The participants
      will be asked to rate the severity of their condition using the hyperhidrosis disease
      severity scale in which a score of 3 or 4 indicates severe hyperhidrosis while a score of 1
      or 2 indicates mild or moderate hyperhidrosis. The therapeutic results will be considered as
      "excellent" or "good" if the patient indicate a reduction of 2 or 1 points, respectively, on
      the HDSS score.

      In addition, quality of life will be assessed by a modified Dermatology Life Quality Index.
      The maximum score is 30, with 0 indicating a negligible effect of the disorder on the
      patient's quality of life and 30 indicating a significant impact. A change of 0-1 point on
      the mDLQI score will be interpreted as reflecting no effect on the patient's life, a change
      of 2-5 points as a small effect, 6-10 points as a moderate effect, 11-20 points as a very
      significant modification, and 21-30 points as the most significant impact possible.

      At the end of the treatment, patients will complete a questionnaire evaluating the following:

        1. Sweat reduction in the treated and in the control sweating areas (0 = no change, 1 =
           poor (limited improvement with the patient being very much aware of sweating), 2 = fair
           (marked improvement, with noticeable sweating under stressful conditions only, 3 = good
           (marked improvement with minimal sweating under stressful conditions), and 4 = excellent
           improvement, with cessation of sweating)

        2. Global patient satisfaction (0 = dissatisfied, 1 = partially satisfied, 2 = satisfied,
           and 3 = highly satisfied).

        3. Side effects: dry mouth, headache, dizziness, urine retention, constipation and
           application site reactions (pruritus or dermatitis).

      All patients will undergo the Minor iodine-starch test. The tested area will be photographed
      under standard conditions using the Galaxy Camera (3G) EK-GC100 photography system.
      Photographs taken before and after 30 days of treatment will be independently assessed by two
      dermatologists who are unaware of the study design. All pairs of photographs will be graded
      as 0 = no change, 1 = minor change of <25%, 2 = moderate change between 25-50%, 3 = major
      change between 50-75%, and 4 = absence or near absence of sweating.

      Both the study and control gels will be compounded in an Israeli compounding pharmacy.

      Continuous variables will be fed into a tabular format as means ± standard errors and
      compared using the Wilcoxon paired test. Categorical variables will be tested using the
      Fisher exact test. Correlation between raters will evaluated using Spearman's correlation.
      All analyses were carried out using SPSS 23.0.2.
allocation: Randomized
intervention model: Single Group Assignment
primary purpose: Treatment
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: The change of Dermatology Life Quality Index (DLQI)
time frame: baseline and following 30 days
measure: the chanhe of Hyperhidrosis Disease Severity Scale (HDSS)
time frame: baseline and following 30 days
measure: sweat reduction grading
time frame: 30 days
measure: satisfaction rate
time frame: 30 days
arm group label: patients with palmar hyperhidrosis
arm group type: Experimental
description: oxybutynin Vs placebo
arm group label: patients with plantar hyperhidrosis
arm group type: Experimental
description: oxybutynin Vs placebo
arm group label: patients with axillary hyperhidrosis
arm group type: Experimental
description: oxybutynin Vs placebo
intervention type: Drug
intervention name: Oxybutynin
description: 10% oxybutynin gel (one side) Vs placebo aqueous gel (other side) - 2/d application, 1 month
arm group label: patients with axillary hyperhidrosis
arm group label: patients with palmar hyperhidrosis
arm group label: patients with plantar hyperhidrosis
other name: anti cholinergic
intervention type: Drug
intervention name: Placebos
arm group label: patients with axillary hyperhidrosis
arm group label: patients with palmar hyperhidrosis
arm group label: patients with plantar hyperhidrosis
criteria: 
gender: All
minimum age: 18 Years
maximum age: 60 Years
healthy volunteers: No
last name: Ofir Artzi, MD
role: Principal Investigator
affiliation: Dermatology department Tel Aviv medical center
citation: Schollhammer M, Brenaut E, Menard-Andivot N, Pillette-Delarue M, Zagnoli A, Chassain-Le Lay M, Sassolas B, Jouan N, Le Ru Y, Abasq-Thomas C, Greco M, Penven K, Roguedas-Contios AM, Dupre-Goetghebeur D, Gouedard C, Misery L, Le Gal G. Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. Br J Dermatol. 2015 Nov;173(5):1163-8. doi: 10.1111/bjd.13973. Epub 2015 Oct 14.
PMID: 26114588
citation: Wolosker N, de Campos JR, Kauffman P, Puech-Leao P. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. J Vasc Surg. 2012 Jun;55(6):1696-700. doi: 10.1016/j.jvs.2011.12.039. Epub 2012 Feb 16.
PMID: 22341836
citation: Try C, Messikh R, Elkhyat A, Aubin F, Humbert RP. [Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis]. Rev Med Liege. 2012 Oct;67(10):520-6. French.
PMID: 23167161
citation: Cartwright R, Srikrishna S, Cardozo L, Robinson D. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence. BJU Int. 2011 Jan;107(1):70-6. doi: 10.1111/j.1464-410X.2010.09508.x.
PMID: 20626389
citation: Sand PK, Davila GW, Lucente VR, Thomas H, Caramelli KE, Hoel G. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome. Am J Obstet Gynecol. 2012 Feb;206(2):168.e1-6. doi: 10.1016/j.ajog.2011.08.005. Epub 2011 Aug 11.
PMID: 21963104
citation: Staskin DR, Dmochowski RR, Sand PK, Macdiarmid SA, Caramelli KE, Thomas H, Hoel G. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol. 2009 Apr;181(4):1764-72. doi: 10.1016/j.juro.2008.11.125. Epub 2009 Feb 23.
PMID: 19233423
responsible party type: Principal Investigator
investigator affiliation: Tel-Aviv Sourasky Medical Center
investigator full name: michal roll
investigator title: DERMATOLOGIST, HEAD, CENTER OF AESTHETIC DERMATOLOGY
mesh term: Hyperhidrosis
mesh term: Oxybutynin
sharing ipd: Undecided